News & Reports

Sign Up for the Policy Watch Newsletter.

Stay updated on the North Bay Leadership Council's latest insights and actions on policies shaping the North Bay community.

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Members In The News Joanne Webster Members In The News Joanne Webster

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Ultragenyx reveals promising interim Phase 1/2 data showing rapid, multi-domain improvements in patients with Angelman syndrome treated with GTX-102, offering new hope for a disease that currently lacks any approved treatment—find out more about these groundbreaking results and what’s next in their development.

Read More